Chesley Taft & Associates LLC Sells 255 Shares of Amgen, Inc. (NASDAQ:AMGN)

Chesley Taft & Associates LLC decreased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,638 shares of the medical research company’s stock after selling 255 shares during the quarter. Chesley Taft & Associates LLC’s holdings in Amgen were worth $3,217,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in AMGN. Quadrant Capital Group LLC raised its holdings in Amgen by 15.2% in the 4th quarter. Quadrant Capital Group LLC now owns 6,686 shares of the medical research company’s stock valued at $1,583,000 after acquiring an additional 883 shares in the last quarter. NumerixS Investment Technologies Inc raised its holdings in Amgen by 120.0% in the 4th quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical research company’s stock valued at $265,000 after acquiring an additional 600 shares in the last quarter. PSI Advisors LLC acquired a new position in Amgen in the 4th quarter valued at approximately $104,000. STA Wealth Management LLC acquired a new position in Amgen in the 4th quarter valued at approximately $302,000. Finally, Blair William & Co. IL raised its holdings in Amgen by 4.7% in the 4th quarter. Blair William & Co. IL now owns 110,580 shares of the medical research company’s stock valued at $26,657,000 after acquiring an additional 4,995 shares in the last quarter. Hedge funds and other institutional investors own 75.75% of the company’s stock.

In other Amgen news, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $229.27, for a total transaction of $229,270.00. Following the completion of the transaction, the director now directly owns 16,482 shares in the company, valued at $3,778,828.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total transaction of $100,856.75. Following the transaction, the director now owns 5,834 shares of the company’s stock, valued at $1,384,466.54. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,425 shares of company stock valued at $792,017. 0.36% of the stock is currently owned by corporate insiders.

Several research firms have commented on AMGN. Mizuho reaffirmed a “hold” rating and issued a $215.00 price target on shares of Amgen in a report on Thursday, April 30th. Cantor Fitzgerald increased their target price on Amgen from $255.00 to $263.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Oppenheimer began coverage on Amgen in a report on Friday, May 1st. They issued a “buy” rating and a $252.00 target price for the company. Wolfe Research began coverage on Amgen in a report on Tuesday, March 31st. They issued a “market perform” rating and a $218.00 target price for the company. Finally, Bank of America increased their target price on Amgen from $250.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eighteen have assigned a buy rating to the stock. Amgen has an average rating of “Buy” and a consensus price target of $245.85.

Shares of AMGN stock opened at $251.59 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16. The stock has a market cap of $148.91 billion, a P/E ratio of 19.72, a price-to-earnings-growth ratio of 2.16 and a beta of 0.94. The stock has a 50 day simple moving average of $231.72 and a 200 day simple moving average of $225.94. Amgen, Inc. has a 1 year low of $173.12 and a 1 year high of $264.97.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.70 by $0.47. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company posted $3.56 earnings per share. Analysts forecast that Amgen, Inc. will post 15.56 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is a Candlestick Chart?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.